Levetiracetam Seacross (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. By stabilizing synaptic transmission, it reduces neuronal hyper‑excitability and helps prevent the initiation and propagation of epileptic discharges.

The specific dose of Levetiracetam Seacross is determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Healthcare professionals set the appropriate dosing regimen and infusion rate.

Levetiracetam is classified as Pregnancy Category B, indicating no evidence of fetal risk in animal studies, but human data are limited. It is excreted in breast milk in small amounts; a risk‑benefit assessment should be performed by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Levetiracetam has a distinct mechanism targeting SV2A and shows minimal drug‑enzyme interactions compared with many older antiepileptics such as carbamazepine or phenytoin. This profile often results in fewer dose adjustments and a lower risk of pharmacokinetic interactions, though individual response varies.

Levetiracetam Seacross should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct light, moisture, and extreme temperature fluctuations to maintain stability.

Levetiracetam Seacross is given as an intravenous infusion. The infusion rate and duration are set by the healthcare professional, typically over 15 minutes to several hours, depending on clinical need and patient tolerance.

Serious risks include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, and the emergence of suicidal thoughts or behaviors. Patients should be monitored closely for any signs of rash, breathing difficulty, or mood changes, and medical attention should be sought immediately if they occur.

Levetiracetam Seacross is contraindicated in patients with known hypersensitivity to levetiracetam or any of the formulation components. Caution is also advised for individuals with severe renal impairment, as dose adjustments may be required, and for those with a history of serious psychiatric disorders.